Oral contraceptives, human papillomavirus and cervical cancer

European Journal of Cancer Prevention

Volumn 23, Issue 2, 2014, Pages 110-112

  La Vecchia, Carlo ^a,b   Boccia, Stefania ^c  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

Author keywords

cervical cancer; epidemiology; human papillomavirus; oral contraceptions; risk

Indexed keywords

CANCER VACCINE; GESTAGEN; INJECTABLE CONTRACEPTIVE AGENT; ORAL CONTRACEPTIVE AGENT;

ARTICLE; CANCER CONTROL; CANCER SCREENING; EASTERN EUROPE; HORMONAL CONTRACEPTION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; LOWEST INCOME GROUP; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; SEXUALITY; SOUTH AND CENTRAL AMERICA; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; WART VIRUS;

CASE-CONTROL STUDIES; CERVICAL INTRAEPITHELIAL NEOPLASIA; CONTRACEPTIVES, ORAL; FEMALE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; RISK FACTORS; UTERINE CERVICAL NEOPLASMS;

EID: 84893536566     PISSN: 09598278     EISSN: 14735709     Source Type: Journal    
DOI: 10.1097/CEJ.0000000000000000     Document Type: Article

References (20)

1. Appleby P, Beral V, Berrington de Gonzalez A, Colin D, Franceschi S, Goodhill A, et al. (2007). Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16 573 women with cervical cancer and 35 509 women without cervical cancer from 24 epidemiological studies. Lancet 370:1609-1621.
2. Bosetti C, Malvezzi M, Chatenoud L, Negri E, Levi F, La Vecchia C (2005). Trends in cancer mortality in the Americas, 1970-2000. Ann Oncol 16: 489-511.
3. Bosetti C, Bertuccio P, Malvezzi M, Levi F, Chatenoud L, Negri E, et al. (2013). Cancer mortality in Europe, 2005-2009, and an overview of trends since 1980. Ann Oncol 24:2657-2671.
4. Chatenoud L, Bertuccio P, Bosetti C, Levi F, Curado MP, Malvezzi M, et al. (2010). Trends in cancer mortality in Brazil, 1980-2004. Eur J Cancer Prev 19:79-86.
5. Cibula D, Gompel A, Mueck AO, La Vecchia C, Hannaford PC, Skouby SO, et al. (2010). Hormonal contraception and risk of cancer. Hum Reprod Update 16:631-650.
6. Crosbie EJ, Einstein MH, Franceschi S, Kitchener HC (2013). Human papillomavirus and cervical cancer. Lancet 382:889-899.
7. De Vuyst H, Clifford G, Li N, Franceschi S (2009). HPV infection in Europe. Eur J Cancer 45:2632-2639.
8. Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, et al. (2012). Global burden of human papillomavirus and related diseases. Vaccine 30 (Suppl 5):F12-F23.
9. Franceschi S, Herrero R, La Vecchia C (2000). Cervical cancer screening in Europe. What next? Eur J Cancer 36:2272-2275.
10. FUTURE II Study Group (2007). Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356: 1915-1927.
11. Guan P, Howell-Jones R, Li N, Bruni L, de Sanjose S, Franceschi S, et al. (2012). Human papillomavirus types in 115789 HPV-positive women: a metaanalysis from cervical infection to cancer. Int J Cancer 131:2349-2359.
12. Kim JJ (2011). The role of cost-effectiveness in U.S. vaccination policy. N Engl J Med 365:1760-1761.
13. La Torre G (2010). Assessment of HPV vaccines: from the burden of dieases to the health technology assessment approach. Hum Vaccin 6:915-917.
14. La Vecchia C, Franceschi S, Decarli A, Fasoli M, Gentile A, Tognoni G (1986). Cigarette smoking and the risk of cervical neoplasia. Am J Epidemiol 123:22-29.
15. La Vecchia C, Bosetti C (2003). Oral contraceptives and cervical cancer: public health implications. Eur J Cancer Prev 12:1-2.
16. La Vecchia C, Bosetti C, Lucchini F, Bertuccio P, Negri E, Boyle P, et al. (2010). Cancer mortality in Europe, 2000-2004, and an overview of trends since 1975. Ann Oncol 21:1323-1360.
17. Moreno V, Bosch FX, Munoz N, Meijer CJ, Shah KV, Walboomers JM, et al. (2002). Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet 359:1085-1092.
18. Paavonen J, Naud P, Salmerón J,Wheeler CM, Chow SN, Apter D, et al. (2009). Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374:301-314.
19. Parazzini F, Chatenoud L, La Vecchia C, Chiaffarino F, Ricci E, Negri E (1998). Time since last use of oral contraceptives and risk of invasive cervical cancer. Eur J Cancer 34:884-888.
20. Smith JS, Green J, Berrington de Gonzalez A, Appleby P, Peto J, Plummer M,et al. (2003). Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet 361:1159-1167.